RLS-0071 is in development for treatment of Acute Lung Injury (ALI) and Hypoxic Ischemic Encephalopathy (HIE) Norfolk, VA, May...
Read MoreProceeds to Fund Programs Addressing Acute Lung Injury (ALI) and Hypoxic Ischemic Encephalopathy (HIE) Norfolk, VA, April 28, 2021 —...
Read MoreNorfolk, VA, April 9, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive...
Read MoreNorfolk, VA, February 16, 2021 – ReAlta Life Sciences, Inc. (“ReAlta”), a company addressing life-threatening diseases through harnessing the power...
Read MoreNorfolk, VA, December 3, 2020 — ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted Orphan...
Read MoreNorfolk, VA, July 28, 2020 — ReAlta Life Sciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has...
Read MoreNorfolk, VA, June 29, 2020 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer,...
Read MoreNorfolk, VA, April 21, 2020 — ReAlta Life Sciences, Inc., today announced that it has successfully closed an oversubscribed Series A2...
Read MoreNorfolk, VA, April 9, 2020 — ReAlta Life Sciences, Inc., a biotech company dedicated to harnessing the power of the immune...
Read More